Erythropoiesis in multiply injured patients

Journal of Trauma - Injury, Infection and Critical Care

Volumn 61, Issue 5, 2006, Pages 1285-1291

  Robinson, Yohan ^a   Hostmann, Arwed ^a   Matenov, Alexander ^a   Ertel, Wolfgang ^a   Oberholzer, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anemia; Erythropoiesis; Erythropoietin; Systemic inflammatory response syndrome; Trauma

Indexed keywords

BLOOD SUBSTITUTE; IRON; RECOMBINANT ERYTHROPOIETIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMYLASE BLOOD LEVEL; ANEMIA; BLEEDING; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG COST; DYSERYTHROPOIESIS; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEVER; HEME SYNTHESIS; HEMOLYSIS; HEMOPERFUSION; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; IRON ABSORPTION; IRON DEFICIENCY; JAUNDICE; META ANALYSIS; MULTIPLE TRAUMA; MYALGIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANEMIA; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; ERYTHROPOIESIS; FLUID THERAPY; HEMORRHAGE; HUMANS; IRON; MULTIPLE TRAUMA; RESUSCITATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33750933743     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/01.ta.0000240969.13891.9b     Document Type: Review

References (78)

1. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med. 2004;32:39-52.
2. Livingston DH, Anjaria D, Wu J, et al. Bone marrow failure following severe injury in humans. Ann Surg. 2003;238:748-753.
3. Baginski S, Körner R, Frei U, Eckardt KU. Anemia and erythropoietin in critically ill patients. Zentralbl Chir. 2003;128:487-492.
4. Napolitano LM, Corwin HL. Efficacy of red blood cell transfusion in the critically ill. Crit Care Clin. 2004;20:255-268.
5. Napolitano L. Cumulative Risks of Early Red Blood Cell Transfusion. J Trauma. 2006;60:S26-S34.
6. Moore EE, Johnson JL, Cheng AM, Masuno T, Banerjee A. Insights from studies of blood substitutes in trauma. Shock. 2005;24:197-205.
7. Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med. 2000;28:N3-N12.
8. Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691-709.
9. Cipolle MD, Pasquale MD, Cerra FB. Secondary organ dysfunction: from clinical perspectives to molecular mediators. Crit Care Clin. 1993;9:261-297.
10. Fosse E, Pillgram-Larsen J, Svennevig JL, et al. Complement activation in injured patients occurs immediately and is dependent on the severity of the trauma. Injury. 1998;29:509-514.
11. Szebeni J, Baranyi L, Savay S, et al. Complement activation during hemorrhagic shock and resuscitation in swine. Shock. 2003;20:347-355.
12. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett. 1995;377:461-464.
13. Gebhard F, Nussler AK, Rosch M, et al. Early posttraumatic increase in production of nitric oxide in humans. Shock. 1998;10:237-242.
14. Laroux FS, Pavlick KP, Hines IN, et al. Role of nitric oxide in inflammation. Acta Physiol Scand. 2001;173:113-118.
15. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999;27:2630-2639.
16. Robinson Y, Cristancho E, Böning D. Intravascular hemolysis and mean red blood cell age in athletes. Med Sci Sports Exerc. 2006;38:480-483.
17. Lang F, Lang KS, Lang PA, Huber SM, Wieder T. Osmotic shock-induced suicidal death of erythrocytes. Acta Physiol (Oxf). 2006;187:191-198.
18. Szygula Z. Erythrocytic system under the influence of physical exercise and training. Sports Med. 1990;10:181-197.
19. van Iperen CE, Kraaijenhagen RJ, Biesma DH, et al. Iron metabolism and erythropoiesis after surgery. Br J Surg. 1998;85:41-45.
20. Jenkins RR. Free radical chemistry. Relationship to exercise. Sports Med. 1988;5:156-170.
21. Halicka D, Strazynski W, Sniegocka B. The osmotic resistance and some morphological features of red blood cells in sportsmen. J Sports Med Phys Fitness. 1969;9:219-223.
22. Santos-Silva A, Rebelo MI, Castro EM, et al. Leukocyte activation, erythrocyte damage, lipid profile and oxidative stress imposed by high competition physical exercise in adolescents. Clin Chim Acta. 2001;306:119-126.
23. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev. 1992;72:449-489.
24. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23:159-162.
25. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18:555-559.
26. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-1994.
27. Hobisch-Hagen P, Wiedermann F, Mayr A, et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med. 2001;29:743-747.
28. Schobersberger W, Hoffmann G, Fandrey J. Nitric oxide donors suppress erythropoietin production in vitro. Pflugers Arch. 1996;432:980-985.
29. Eisenstein RS, Ross KL. Novel roles for iron regulatory proteins in the adaptive response to iron deficiency. J Nutr. 2003;133:1510S-1516S
30. Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA. 1996;93:8175-8182.
31. Mullner EW, Neupert B, Kuhn LC. A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA. Cell. 1989;58:373-382.
32. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today. 1995;16:495-500.
33. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma. 1998;44:361-367.
34. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med. 2003;31(Suppl):S651-S657.
35. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906-19912.
36. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003;101:4148-4154.
37. Milward EA, Trinder D, Wilcox CEJ, et al. Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anaemia of chronic disease. Hepatology. 2005;41:936-937.
38. Weiss G. Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol. 2005;18:183-201.
39. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol. 2002;169:2204-2209.
40. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 2002;8:240-246.
41. Rafferty SP, Domachowske JB, Malech HL. Inhibition of hemoglobin expression by heterologous production of nitric oxide synthase in the K562 erythroleukemic cell line. Blood. 1996;88:1070-1078.
42. Furukawa T, Kohno H, Tokunaga R, Taketani S. Nitric oxide-mediated inactivation of mammalian ferrochelatase in vivo and in vitro: possible involvement of the iron-sulphur cluster of the enzyme. Biochem J. 1995;310(Pt 2):533-538.
43. Zoller H, Decristoforo C, Weiss G. Erythroid 5-aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-dependent regulation. Br J Haematol. 2002;118:619-626.
44. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia. 2004;18:1176-1199.
45. Liu Y, Pop R, Sadegh C, et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress-response in vivo. Blood. 2006;108:123-133.
46. Obinata M, Yanai N. Cellular and molecular regulation of an erythropoietic inductive microenvironment (EIM). Cell Struct Funct. 1999;24:171-179.
47. Ferguson KL, Taheri P, Rodriguez J, et al. Tumor necrosis factor activity increases in the early response to trauma. Acad Emerg Med. 1997;4:1035-1040.
48. Schubert T, Echtenacher B, Hofstädter F, Männel DN. TNF-independent development of transient anemia of chronic disease in a mouse model of protracted septic peritonitis. Lab Invest. 2003;83:1743-1750.
49. Trey JE, Kushner I. The acute phase response and the hematopoietic system: the role of cytokines. Crit Rev Oncol Hematol. 1995;21:1-18.
50. Sudo T, Ito M, Ogawa Y, et al. Interleukin 7 production and function in stromal cell-dependent B cell development. J Exp Med. 1989;170:333-338.
51. Wu JC, Livingston DH, Hauser CJ, Deitch EA, Rameshwar P. Trauma inhibits erythroid burst-forming unit and granulocyte-monocyte colony-forming unit growth through the production of TGF-β1 by bone marrow stroma. Ann Surg. 2001;243:224-232.
52. Rodríguez Mdel C, Bernad A, Aracil M. Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. Blood. 2004;103:3349-3354.
53. Kapur R, Majumdar M, Xiao X, et al. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood. 1998;91:879-889.
54. Yanai N, Sekine C, Yagita H, Obinata M. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood. 1994;83:2844-2850.
55. Spring FA, Parsons SF, Ortlepp S, et al. Intercellular adhesion molecule-4 binds alpha(4)beta(1) and alpha(V)-family integrins through novel integrin-binding mechanisms. Blood. 2001;98:458-466.
56. Goltry KL, Patel VP. Specific domains of fibronectin mediate adhesion and migration of early murine erythroid progenitors. Blood. 1997;90:138-147.
57. Fonseca RB, Mohr AM, Wang L, et al. Adrenergic modulation of erythropoiesis following severe injury is mediated through bone marrow stroma. Surg Infect. 2004;5:385-393.
58. Jacobsen K, Kravitz J, Kincade PW, Osmond DG. Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood. 1996;87:73-82.
59. Hess JR, Zimrin AB. Massive blood transfusion for trauma. Curr Opin Hematol. 2005;12:488-492.
60. Johnson JL, Moore EE, Gonzalez RJ, et al. Alteration of the postinjury hyperinflammatory response by means of resuscitation with a red cell substitute. J Trauma. 2003;54:133-140.
61. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma. 2003;54:898-905.
62. Silliman CC, Moore EE, Johnson JL, Gonzalez RJ, Biffl WL. Transfusion of the injured patient: proceed with caution. Shock. 2004;21(4):291-299.
63. Nathens AB. Massive transfusion as a risk factor for acute lung injury: association or causation? Crit Care Med. 2006;34(5 Suppl):S144-S150.
64. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt). 2004;5:395-404.
65. Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des. 2005;11(31):4099-4114.
66. Nuttall GA, Stehling LC, Beighley CM, Faust RJ. American Society of Anesthesiologists Committee on Transfusion Medicine. Current transfusion practices of members of the american society of anesthesiologists: a survey. Anesthesiology. 2003;99:1433-1443.
67. Turgeon AF, Fergusson DA, Doucette S, et al. Red blood cell transfusion practices amongst Canadian anesthesiologists: a survey. Can J Anaesth. 2006;53:344-352.
68. McIntyre L, Hebert PC, Wells G, et al. Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma. 2004;57:563-568.
69. Earley AS, Gracias VH, Haut E, et al. Anemia Management Program Reduces Transfusion Volumes, Incidence of Ventilator-Associated Pneumonia, and Cost in Trauma Patients. J Trauma. 2006;61:1-7.
70. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2002;(2):CD002042.
71. Moore EE, Cheng AM, Moore HB, Masuno T, Johnson JL. Hemoglobin-Based Oxygen Carriers in Trauma Care: Scientific Rationale for the US Multicenter Prehosptial Trial. World J Surg. 2006;30:1247-1257.
72. Corwin HL. The role of erythropoietin therapy in the critically ill. Transfus Med Rev. 2006;20:27-33.
73. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27:2346-2350.
74. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
75. Georgopoulos D, Matamis D, Routsis C, et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study. Crit Care. 2005;9:R508-515.
76. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95.
77. Dutton RP, Carson JL. Indications for early red blood cell transfusion. J Trauma. 2006;60:S35-S40.
78. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythopoiesis. Blood. 2000;96:823-833.